Polaris Pharmaceutical-KY Announces Board Approval of Consolidated Financial Report for Q1 FY2026

1. Date of Board Meeting or Resolution: 115/05/12 2. Date of Audit Committee Approval: 115/05/12 3. Reporting Period for Financial Report or Self-Compiled Financial Information (Start Date ~ End Date): 115/01/01 ~ 115/03/31 4. Cumulative Operating Revenue from Jan 1 to Current Period (in thousands of NTD): 37,091 5. Cumulative Gross Profit (Loss) from Jan 1 to Current Period (in thousands of NTD): (45,961) 6. Cumulative Operating Income (Loss) from Jan 1 to Current Period (in thousands of NTD): (556,353) 7. Cumulative Profit (Loss) Before Tax from Jan 1 to Current Period (in thousands of NTD): (555,884) 8. Cumulative Net Profit (Loss) for the Period from Jan 1 to Current Period (in thousands of NTD): (553,785) 9. Cumulative Net Profit (Loss) Attributable to Owners of the Parent from Jan 1 to Current Period (in thousands of NTD): (553,785) 10. Cumulative Basic Earnings (Loss) Per Share from Jan 1 to Current Period (in NTD): (0.64) 11. Total Assets at End of Period (in thousands of NTD): 7,628,591 12. Total Liabilities at End of Period (in thousands of NTD): 2,828,590 13. Net Equity Attributable to Owners of the Parent at End of Period (in thousands of NTD): 4,800,001 14. Other Matters to be Noted: None